Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement

Hematology
Kento UminoYoshinobu Kanda

Abstract

Myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement are hematopoietic stem cell disorders with a poor prognosis, but no established standard therapy. We experienced a patient with T-lymphoblastic lymphoma (LBL) associated with FGFR1 rearrangement who underwent cord blood transplantation, but died of pulmonary complication. We collected the clinical data of patients with FGFR1 rearrangement from the medical literature and analyzed 45 patients, including our patient. The primary diagnoses were myeloproliferative neoplasm (MPN) or myelodysplastic syndromes (MDS) in 14 and acute leukemia or LBL in 31. In MPN and MDS patients, the cumulative incidence of transformation to blast phase (BP) at 12 months was 46.2%. The 1-year overall survival (OS) from diagnosis in all cases was 43.1%. With regard to the impact of treatment response on survival, the achievement of complete response with a landmark at 2 months after diagnosis of BP was associated with a superior OS (40.0% vs. 26.0% P = 0.011 for 1-year OS from BP). Allogeneic hematopoietic stem cell transplantation (HSCT) was performed in 13 patients, and the 1-year OS from allogeneic HSCT was 61.5%. The hazard ratio for mortality was 0.34 (95% CI, ...Continue Reading

References

Dec 1, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·José L VizmanosNicholas C P Cross
Dec 21, 2004·Genes, Chromosomes & Cancer·Elena BelloniPier Paolo Di Fiore
Aug 2, 2006·European Journal of Haematology·Katsuya YamamotoToshimitsu Matsui
Jan 22, 2008·Genes, Chromosomes & Cancer·Claire Hidalgo-CurtisFrancis H Grand
Oct 16, 2009·Journal of Pediatric Hematology/oncology·Wenyong W ZhangDolores López-Terrada
Mar 17, 2010·Human Pathology·Courtney C JacksonRoberto N Miranda
Mar 23, 2013·BMJ Case Reports·Alexios MatikasMaria Bakiri
Apr 24, 2013·International Journal of Hematology·Hyeyoung LeeHee-Je Kim
Aug 16, 2015·American Journal of Clinical Pathology·Francisco VegaRoberto N Miranda
May 3, 2016·Blood Reviews·Kuldeepsinh Rana, Keith B Neeves
Oct 28, 2016·British Journal of Haematology·John K CowellMingqiang Ren

❮ Previous
Next ❯

Citations

Sep 5, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Aaron T GerdsHema Sundar
Sep 14, 2021·Frontiers in Cell and Developmental Biology·Lei ChenYu-Dong Cai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.